icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Digital Experience
November 13 - 16 - 2021
Back grey_arrow_rt.gif
HBV pgRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued NrtI treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open-label study
  AASLD2019: Continued Therapy with ABI-H0731 + NrtI Results in Sequential Reduction/Loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg-Positive Patients - (12/02/19)
AASLD 2021 Nov 12-15
Man-Fung Yuen1, Xiaoli Ma2, Tarek I Hassanein3, Paul Yien Kwo4, Julie Ma5, Lewyn Li5, Katie Kitrinos5, Steven J Knox5, Luisa M Stamm5, Ho Bae6, Mark S Sulkowski7, Magdy Elkhashab8, Kosh Agarwal9
1Department of Medicine, The University of Hong Kong, Hong Kong; 2Office of Xiaoli Ma, Philadelphia, PA, USA; 3Southern California Research Center, Coronado, CA, USA; 4Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA; 5Assembly Biosciences, Inc, South San Francisco, CA, USA; 6St. Vincent Medical Center, Asian Pacific Liver Center, Los Angeles, CA, USA; 7Johns Hopkins School of Medicine, Baltimore, MD, USA; 8Toronto Liver Centre, Toronto, ON, Canada; 9Institute of Liver Studies, King's College Hospital, London, UK